Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05070754
Other study ID # 106689
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date December 2, 2021
Est. completion date December 31, 2022

Study information

Verified date March 2024
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum. The treatment device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the virus from the body. Based on the successes of previous dermatologic studies, FE-DBD is being tested for this study to treat warts and molluscum. Patients will be enrolled to test the efficacy and safety of this device. The duration of the study is 4-12 weeks depending on treatment clearance. The number of lesions will be chosen by the dermatologist. Patients will receive standard of care therapy and/or NTAP depending on the number of lesions.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 4 Years to 21 Years
Eligibility Inclusion Criteria: - All patients from 4-21 years old with at least 1 lesion of either verruca vulgaris or molluscum contagiosum - Willingness of the participant and their guardian to provide consent when applicable Exclusion Criteria: - Unwillingness to participate in the study - Received any treatment on the lesion in the past month, as determined by review of participant medical record - Immunodeficiency as determined by review of participant medical record - Adverse response to prior treatments as determined by review of medical record - Signs of self-resolution as determined by study team members - Conditions that lead to excessive scarring as determined by study team members - Facial and genital lesions as determined by study team members

Study Design


Intervention

Device:
Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
Cryotherapy
Cryotherapy refers to the application of liquid nitrogen using a cryospray device in order to freeze a lesion of interest. Treatment is repeated every few weeks until the lesion of interest has disappeared. It is considered SOC for the treatment of warts.
Drug:
Canthardin Collodion
Chemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina The Skin Center Dermatology Group

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numbers of Lesions With no Response Absence of change in appearance of targeted lesion. Molluscum is defined as the visualization of a central umbilication with polylobular, white to yellow, amorphous structures. A peripheral crown of radiating or punctiform vessels may also be present. Warts are defined as grouped papillae, with dotted or loop vessels, and/or hemorrhagic points and lines often surrounded by a whitish halo. 12 weeks
Primary Numbers of Lesions With Partial Response There is change in the size, dyspigmentation, or discomfort of the targeted lesion as compared to its appearance and symptoms at the initial visit, but the lesion remains grossly visible. Molluscum is defined as the visualization of a central umbilication with polylobular, white to yellow, amorphous structures. A peripheral crown of radiating or punctiform vessels may also be present. Warts are defined as grouped papillae, with dotted or loop vessels, and/or hemorrhagic points and lines often surrounded by a whitish halo. Changes in the characteristics of the targeted lesions will be evaluated by a dermatologist and documented via photographs at follow-up visits at 4, 8, and 12 weeks, with the final outcome measured at the 12-week visit. 12 weeks
Primary Numbers of Lesions With Complete Response Targeted lesion is no longer grossly visible. 12 weeks
Secondary Post-Treatment CAP Tolerability Questionnaire This questionnaire measures tolerability of cold atmospheric plasma treatment. Assessment of dryness, peeling, scaling, erythema, edema, stinging, burning sensation, itching, scarring and dyspigmentation will each be assessed individually. Participants were asked about these symptoms at a 1-week post-first treatment phone call, and then at every in-person follow up visit. Outcome data represents the number of total lesions in each treatment group in which a participant reported at least one of the above adverse symptoms. Results of specific AEs are detailed in the Adverse Event section. 12 weeks
Secondary Score of Visual Analogue Scale Associated With Treatment The visual analogue scale (VAS) is a validated subjective measurement of pain experienced by the patient. It consists of visual-numeric scale, numbered from 0-10. (0) indicate absence of pain or "no pain at all", while (10) indicates severe pain or "worst imaginable pain". This is supplemented by six faces with different expressions, ranging from happy to extremely upset. Each facial expression is assigned a numerical scale from 0 to 10. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05937672 - Cold Atmospheric Plasma Device Extension Study Phase 3
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Recruiting NCT05409365 - Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Completed NCT01084824 - A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin N/A
Terminated NCT01609530 - Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy N/A
Recruiting NCT04620785 - Photodynamic Therapy in Treatment of Verrucae N/A
Completed NCT04793529 - Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study N/A
Recruiting NCT05799157 - Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts Phase 2
Completed NCT02748902 - Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands. Phase 1
Completed NCT02483455 - ALC-919 For The Treatment Of Common Warts Phase 2